USD
GBP
CNY
EUR
INR
JPY
MYR
ZAR
KRW
THB
Strategic Analysis of the European Therapeutic Monoclonal Antibodies (Non-Cancer) Market
Strategic Analysis of the European Therapeutic Monoclonal Antibodies (Non-Cancer) Market
08-Apr-2003
Europe
$4,950.00
Special Price $3,712.50 save 25 %
Description
This report will address the products and molecules currently in phase II to launch phase and their potential applications in the segments highlighted below. It will include products that Frost & Sullivan predict will be launched within the forecast period of 2002 to 2010. The success of a product through phase III trials is obviously not guaranteed, with around a 30 percent failure rate. Therefore, this report must be based on a number of assumptions, all of which will be highlighted throughout. Products already available on the market, as well as competitive situation will be addressed. Each segment will be researched on a European level, with any specific country challenges and trends identified.
Table of Contents
Market Overview
- Introduction and Presentation
Therapeutic Mabs
- Overview
- Technology Trends
Acronyms
- Acronyms
Identification of the Challenges Facing the European Therapeutic Monoclonal Antibodies Market
Market Engineeing Strategic Recommendations
Overview of the Current Situation
Key Companies and Research and Marketing Collaborations
- R and D: Autoimmune and Inflammatory Disease
- R and D: Organ Transplant
- R and D: Cardiovascular Disorders
- R and D: Infectious Disease
Recent Research Collaborations
- Overview
- Abgenix
- Abgenix and Sangstat
- Alexion and Proctor & Gamble
- CAT and Abbott
- Celltech and Biogen
- Celltech and Pharmacia
- Centecor and Eli Lilly
- Elan and Biogen
- Genentech Xoma and Serono
- Genmab
- IDEC Pharmaceuticals
- Medarex
- Medimmune
- Millennium
- Novartis
- Roche and PDL
- Serono and Genentech
- Schering Plough
Overview of Products in Late Stage Development for Autoimmune Disease
- Abbott and Medarex
- Chugai and Abgenix
- MorphoSys and Boehringer Ingelheim
Overview of Products in Late Stage Development for Organ Transplant
- Elan/Biogen: Antegren
- Celltech/Pharmacia: CDP 870
- CAT/Abbott: Humara
- Celltech/Biogen: Humicade
- ILEX Oncology: CAMPATH
- Medimmune/Biotransplant: Siplizumab (MEDI-507)
- Protein Design Labs/Roche: Daclizumab
- Roche: MabThera (Rituximab)
- Alexion: Eculizumab
- Genentech/Xoma: Raptiva
- Genentech/Novartis/Tanox: Xolair
- Genmab/Amgen: HuMax IL15
- Genmab: HuMax CD4
Overview of Products in Development (Other Disease Areas)
- Abgenix/Sangstat: ABX-CBL - Discontinued
- Protein Design Labs: Nuvion
- Roche: Zenapax
Market Overview
Market Forecasts
Competitive Analysis
Disease and Treatment Overview
Epidemiology and Potential Treatable Population
Country Specific Issues
Market Forecasts
Major Product Forecasts
Competitive Analysis
Market Overview
Market Forecasts
Product Trends and Uptake
Competitive Anaylsis
Overview
Current and Future Market Situation
Competitive Situation
Market Overview
Current & Future Market Situation
Popular Topics
| No Index | Yes |
|---|---|
| Podcast | No |
| Industries | Healthcare |
| WIP Number | 3884-01-00-00-00 |
| Is Prebook | No |